Comparison · NCT02014584-05f5cf76
Dutasteride 0.5 mg vs Placebo: Number of Participants With Treatment-related AEs in the Double-blind Treatment Period
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Dutasteride 0.5 mg vs Placebo: Number of Participants With Treatment-related AEs in the Double-blind Treatment Period. Trial comparisons, record NCT02014584-05f5cf76. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT02014584-05f5cf76
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.19 | 0.109 | 0.309 | wilson | |
| Risk in group 2 | 0.0847 | 0.0367 | 0.184 | wilson | |
| Risk difference, group 1 minus group 2 | 0.105 | -0.0224 | 0.233 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 2.24 | 0.829 | 6.04 | log | |
| Odds ratio, group 1 over group 2 | 2.53 | 0.819 | 7.8 | log | |
| Number needed to treat, for one more participant with the outcome on Dutasteride 0.5 mg than on Placebo | 9.53 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Dutasteride 0.5 mg | Participants received dutasteride 0.5 mg administered orally once daily for 24 weeks. | 11 | 58 | OG001 |
| Group 2 | Placebo | Participants received placebo administered orally once daily for 24 weeks. | 5 | 59 | OG000 |
Source ClinicalTrials.gov
Outcome
- Type
- SECONDARY
- Title
- Number of Participants With Treatment-related AEs in the Double-blind Treatment Period
- Description
An AE is defined as any untoward medical occurrence in a patient or clinical investigation participant, temporally associated with the use of a medicinal product, whether or not considered related to the medicinal product. Treatment related AE included events which the investigator classified as having a reasonable possibilty of being caused by the investigational product or whose classification was missing.
- Time frame
- 24 weeks
- Population
- Safety Population
Source ClinicalTrials.gov
Trial
- Title
- Sexual Function in Men Receiving Dutasteride for Androgenetic Alopecia
- NCT number
- NCT02014584
- Phases
- PHASE3
- Conditions
- Alopecia
- Interventions
- Dutasteride, Placebo
- Lead sponsor
- Stiefel, a GSK Company
- Results first posted
- 2017-03-08
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT02014584?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT02014584-05f5cf76